Results 41 to 50 of about 5,421 (159)

The rising dominance of microbiology: what to expect in the next 15 years?

Microbial Biotechnology, Volume 15, Issue 1, Page 110-128, January 2022., 2022
Microbial research could lead to the development of in‐situ and ex‐situ rapid microbial detection systems based on microbial dark matter in the next 15 years. As a result of this anticipated shift, microbial cultivation will rapidly rise, altering the diversity of microorganisms and underlying lineages.
Roshan Kumar, Utkarsh Sood, Jasvinder Kaur, Shailly Anand, Vipin Gupta, Kishor Sureshbhai Patil, Rup Lal   +6 more
wiley   +1 more source

A randomized, double‐blind, placebo‐ and positive‐controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects

Clinical and Translational Science, 2021
Durlobactam (formerly ETX2514) is a diazabicyclooctane β‐lactamase inhibitor that inhibits class A, C, and D β‐lactamases. Sulbactam combined with durlobactam has in vitro and in vivo activity against Acinetobacter baumannii including carbapenem‐ and ...
John O’Donnell, Kathleen Maloney, Melissa Steidler, Royce Morrison, Robin Isaacs   +4 more
doaj   +1 more source

Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections

Clinical Infectious Diseases, 2023
Abstract Antimicrobial resistance in gram-negative pathogens, such as Acinetobacter baumannii, is a serious threat to human health. Sulbactam-durlobactam, a unique β-lactam and a β-lactamase inhibitor combination, is a novel agent targeted against carbapenem-resistant A. baumannii. This supplement provides a summary of the development of
Watkins, Richard R, Bonomo, Robert A
openaire   +2 more sources

In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii

Journal of Antimicrobial Chemotherapy, 2020
AbstractObjectivesTo evaluate the activity of the novel broad-spectrum serine β-lactamase inhibitor durlobactam (ETX2514) combined with sulbactam against global isolates of carbapenem-resistant Acinetobacter baumannii with defined carbapenem resistance mechanisms compared with reference antimicrobials with known activity against Acinetobacter spp ...
Harald Seifert, Carina Müller, Danuta Stefanik, Paul G Higgins, Alita Miller, Michael Kresken   +5 more
openaire   +2 more sources

In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China

Journal of Antimicrobial Chemotherapy, 2020
AbstractBackgroundDurlobactam is a broad-spectrum inhibitor of class A, C and D β-lactamases. Sulbactam is a generic β-lactam most commonly used as a β-lactamase inhibitor in combination with ampicillin; however, it has a unique property in that it has selective intrinsic activity against Acinetobacter baumannii.
Harald Reinhart, Patricia A Bradford, Meredith Hackel, Jun Deng, Ge Zhang, Jingjia Zhang, Ying Zhu, Peiyao Jia, Yingchun Xu, Qiwen Yang   +9 more
openaire   +2 more sources

Activity of ampicillin-sulbactam, sulbactam-durlobactam, and comparators against <i>Acinetobacter baumannii-calcoaceticus</i> complex strains isolated from respiratory and bloodstream sources: results from ACNBio study. [PDF]

Antimicrob Agents Chemother
Infections caused by carbapenem-resistant complex (ABC) are associated with high mortality rates and limited treatment options. This study aims to evaluate the activity of clinically utilized antimicrobials against a contemporary collection of ABC ...
Buyukyanbolu E, Argotsinger J, Beck ET, Chamberland RR, Clark AE, Daniels AR, Liesman R, Fisher M, Gialanella P, Hand J, Harrington AT, Humphries RM, Huse H, Hamilton-Seth R, Hankins JD, Kufel WD, Riddell SW, Marino J, Westblade LF, Mochon AB, Narayanan N, Kirn TJ, Pierce VM, Potula R, Tekle T, Simner PJ, Tibbetts RJ, Vu C, Abbo LM, Martinez O, Dumm RE, Nicolau DP, Asempa TE, Acinetobacter baumannii Complex National Biorepository (ACNBio) Study Group.   +33 more
europepmc   +2 more sources

In vitro activity of cefiderocol and sulbactam-durlobactam against clinical-isolated carbapenem-resistant Acinetobacter baumannii from China

International Journal of Infectious Diseases
Objectives: This study aimed to evaluate the in vitro activity of cefiderocol and sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolates from China and elucidate potential resistance mechanisms.
Yixin Zhang, Mohan Ju, Yumiao Guo, Jinhong Chen, Pei Li, Ying Li   +5 more
doaj   +1 more source

Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory

Antibiotics, 2023
The rapid emergence of multi-drug resistant Gram-negative pathogens has driven the introduction of novel β-lactam combination agents (BLCs) to the antibiotic market: ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem ...
Carmella Russo, Romney Humphries
doaj   +1 more source

Boronic Acid Inhibitors of β‐Lactamases: A Promising Strategy Against Antimicrobial Resistance

Medicinal Research Reviews, EarlyView.
ABSTRACT The rise of antimicrobial resistance (AMR) poses a critical threat to global health, mostly due to the proliferation of β‐lactamases, a class of enzymes responsible for the inactivation of β‐lactam antibiotics. Among the most promising strategies to restore β‐lactam efficacy is the use of β‐lactamase inhibitors (BLIs), with boronic acid ...
Nicolò Santi, Federico Corsini, Robert A. Bonomo, Emilia Caselli, Fabio Prati   +4 more
wiley   +1 more source

Failure of durlobactam to restore the susceptibility to meropenem in carbapenem-resistant Klebsiella pneumoniae

Journal of Global Antimicrobial Resistance
Objective: Durlobactam, a diazabicyclooctane β-lactamase inhibitor, can protect meropenem from hydrolysis of KPC and OXA-48 carbapenemases. This study aims to characterise the genome of a carbapenem-resistant Klebsiella pneumoniae clinical strain with a ...
Hongxia Wen, Yu Feng, Zhiyong Zong
doaj   +1 more source